Dose Dense TC + Pegfilgrastim Support for Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Female Breast Cancer
Interventions
DRUG

docetaxel + cyclophosphamide + pegfilgrastim

docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of Wisconsin, Madison

OTHER